Literature DB >> 27365543

Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS.

D Fischer1, C Reisenbüchler1, S Rösner2, J Haussmann1, P Wimberger1, M Goeckenjan1.   

Abstract

The polycystic ovary syndrome is a common endocrine disorder which influences outcome and potential risks involved with controlled ovarian stimulation for artificial reproductive techniques (ART). Concrete practical recommendations for the dosage of gonadotropins, the preferred protocol and preventive methods to avoid ovarian hyperstimulation syndrome (OHSS) are lacking. We present retrospective data of 235 individually calculated gonadotropin low-dose stimulations for ART in a single center from 2012 to 2014. Clinical data and outcome parameter of patients diagnosed with PCOS according to Rotterdam criteria (n = 39) were compared with patients without PCOS (n = 196). The starting dose of gonadotropins was individually calculated depending on patients' age, BMI, ovarian reserve, ovarian response in previous cycles, and diagnostic criteria of PCOS. Mean age and duration of infertility did not differ between the groups, whereas mean BMI (p = 0.007) and AMH (p < 0.001) were higher in the PCOS-group. A lower mean FSH-starting and maximum dose was administered to women with PCOS (p < 0.001). The biochemical pregnancy rate of 42.4 % and the clinical pregnancy rate of 32.2 % for PCOS-patients did not differ from those of the control group (42.2 % and 34.4 % respectively). Neither mild, nor moderate or severe manifestation of OHSS occurred significantly more often in patients with PCOS. Our study supports the use of a calculated low-dose FSH-stimulation strategy in ART for patients with PCOS. Further randomized clinical trials should confirm this strategy and lead to define individual risk factors for OHSS, which can be used for recommendation of safer ART-techniques like in vitro maturation.

Entities:  

Keywords:  ART; IVF/ICSI; PCOS; gonadotropins; ovarian hyperstimulation syndrome (OHSS)

Year:  2016        PMID: 27365543      PMCID: PMC4922889          DOI: 10.1055/s-0042-100206

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  32 in total

1.  Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.

Authors:  A P Yates; O Rustamov; S A Roberts; H Y N Lim; P W Pemberton; A Smith; L G Nardo
Journal:  Hum Reprod       Date:  2011-06-13       Impact factor: 6.918

Review 2.  Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches.

Authors:  Peter Humaidan; Lawrence Engmann; Claudio Benadiva
Journal:  Fertil Steril       Date:  2015-02-11       Impact factor: 7.329

3.  IVF outcome in women with PCOS, PCO and normal ovarian morphology.

Authors:  Alexander Swanton; Lisa Storey; Enda McVeigh; Tim Child
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2009-12-22       Impact factor: 2.435

4.  The influence of obesity on ICSI outcomes in women with polycystic ovary syndrome.

Authors:  M T Ozgun; S Uludag; G Oner; C Batukan; E M Aygen; Y Sahin
Journal:  J Obstet Gynaecol       Date:  2011       Impact factor: 1.246

5.  A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome.

Authors:  E M E W Heijnen; M J C Eijkemans; E G Hughes; J S E Laven; N S Macklon; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2005-08-25       Impact factor: 15.610

6.  Ovarian hyperstimulation syndrome: steps to maximize success and minimize effect for assisted reproductive outcome.

Authors:  Puja S Gera; Laura L Tatpati; Michael C Allemand; Mark A Wentworth; Charles C Coddington
Journal:  Fertil Steril       Date:  2009-04-07       Impact factor: 7.329

7.  Effects of polycystic ovarian syndrome on in vitro fertilization-embryo transfer outcomes are influenced by body mass index.

Authors:  Betsy McCormick; Michael Thomas; Rose Maxwell; Daniel Williams; Mira Aubuchon
Journal:  Fertil Steril       Date:  2008-01-14       Impact factor: 7.329

8.  Impact of polycystic ovary syndrome on selected indicators of in vitro fertilization and intracytoplasmic sperm injection treatment success.

Authors:  Hind A Beydoun; Laurel Stadtmauer; Yueqin Zhao; Helena Russell; David O Matson; Sergio Oehninger
Journal:  J Womens Health (Larchmt)       Date:  2009-05       Impact factor: 2.681

9.  GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.

Authors:  P Humaidan; N P Polyzos; B Alsbjerg; K Erb; A L Mikkelsen; H O Elbaek; E G Papanikolaou; C Y Andersen
Journal:  Hum Reprod       Date:  2013-06-09       Impact factor: 6.918

10.  Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization.

Authors:  Ayse Figen Turkcapar; Berna Seckin; Gogsen Onalan; Tulin Ozdener; Sertac Batioglu
Journal:  Int J Fertil Steril       Date:  2013-03-03
View more
  8 in total

1.  Follicular fluid PlGF and IVF/ICSI outcomes among PCOS and normo-ovulatory women using different controlled hyperstimulation protocols: A prospective case-control study.

Authors:  Sally Kadoura; Marwan Alhalabi; Abdul Hakim Nattouf
Journal:  Ann Med Surg (Lond)       Date:  2022-06-25

2.  Inositol for subfertile women with polycystic ovary syndrome.

Authors:  Marian G Showell; Rebecca Mackenzie-Proctor; Vanessa Jordan; Ruth Hodgson; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2018-12-20

3.  The effects of di(2-ethylhexyl) phthalate exposure in women with polycystic ovary syndrome undergoing in vitro fertilization.

Authors:  Yue Jin; Qing Zhang; Jie-Xue Pan; Fang-Fang Wang; Fan Qu
Journal:  J Int Med Res       Date:  2019-11-10       Impact factor: 1.671

4.  Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series.

Authors:  Stephanie Yacoub; Kenneth Cadesky; Robert F Casper
Journal:  J Ovarian Res       Date:  2021-02-12       Impact factor: 4.234

5.  Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.

Authors:  Sally Kadoura; Marwan Alhalabi; Abdul Hakim Nattouf
Journal:  Sci Rep       Date:  2022-03-15       Impact factor: 4.379

6.  The Essential Role of Body Weight in Adjusting Gn Dosage to Prevent High Ovarian Response for Women With PCOS During IVF: A Retrospective Study.

Authors:  Rujun Zeng; Hanxiao Chen; Xun Zeng; Lang Qin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-01       Impact factor: 6.055

7.  lncRNA PVT1/MicroRNA-17-5p/PTEN Axis Regulates Secretion of E2 and P4, Proliferation, and Apoptosis of Ovarian Granulosa Cells in PCOS.

Authors:  Gelin Liu; Shengxian Liu; Guanlin Xing; Fang Wang
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-13       Impact factor: 8.886

8.  Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study.

Authors:  Jialyu Huang; Qin Xie; Jiaying Lin; Xuefeng Lu; Jing Zhu; Hongyuan Gao; Renfei Cai; Yanping Kuang
Journal:  Drug Des Devel Ther       Date:  2019-12-31       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.